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Abstract
Huntington's disease (HD) is characterized by striatal medium spiny neuron (MSN) dysfunction, 
but the underlying mechanisms remain unclear. We explored roles for astrocytes, which display 
mutant huntingtin in HD patients and mouse models. We found that symptom onset in R6/2 and 
Q175 HD mouse models is not associated with classical astrogliosis, but is associated with 
decreased Kir4.1 K+ channel functional expression, leading to elevated in vivo levels of striatal 
extracellular K+, which increased MSN excitability in vitro. Viral delivery of Kir4.1 channels to 
striatal astrocytes restored Kir4.1 function, normalized extracellular K+, recovered aspects of 
MSN dysfunction, prolonged survival and attenuated some motor phenotypes in R6/2 mice. These 
findings indicate that components of altered MSN excitability in HD may be caused by heretofore 
unknown disturbances of astrocyte–mediated K+ homeostasis, revealing astrocytes and Kir4.1 
channels as novel therapeutic targets.
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Astrocytes contribute to the function of neurons and the brain1-3. There is also growing 
appreciation that astrocytes contribute to neurological and psychiatric diseases2,4-6. HD is an 
autosomal dominant disorder characterized by progressive motor, cognitive and psychiatric 
disturbances associated with neuronal dysfunction and atrophy of the striatum and other 
brain regions. HD is caused by an expanded chain of polyglutamines localized to the N-
terminal region of the huntingtin protein (HTT) that causes intracellular accumulation and 
aggregation of mutant huntingtin7. The physiological role of HTT and the mechanisms that 
produce the disease are largely unknown, although intense effort has focused on the study of 
mutant huntingtin (mHTT) expression on neuronal function, particularly in the striatum8. 
Recent studies suggest that astrocytes may also be involved in HD. Thus, brains from HD 
patients and from mouse models of HD show accumulation of mHTT in striatal 
astrocytes9,10. Selective expression of mHTT only in astrocytes leads to cell death of striatal 
neurons9, reduced glutamate transporter expression10 and age–dependent broadly HD–like 
pathology11. However, these studies do not prove that astrocyte physiology is altered in 
conventional mouse models of HD.
An appraisal of existing animal models of HD does not reveal that any one is superior12, and 
so we explored astrocyte physiology in two mouse models of HD: an early onset well 
established “aggressive” exon 1 human mHTT transgenic R6/2 model7 and the more slowly 
developing knock–in Q175 model13,14. We found that Kir4.1 potassium ion channel 
expression was significantly decreased in astrocytes that express mHTT, with little or no 
evidence for reactive astrogliosis at stages corresponding with initial onset of symptoms in 
both mouse models. The loss of a resting K+ conductance depolarized astrocytes and likely 
contributed to the elevated levels of K+ that we measured in vivo within the striatum of HD 
model mice. Moreover, we found that these subtly elevated extracellular K+ levels (by ∼2 
mM) significantly depolarized medium spiny neurons (MSN) and increased their 
excitability. Conversely, rescuing the loss of astrocyte Kir4.1 channels ameliorated several 
deficits associated with HD mouse models. We propose the novel hypothesis that some 
features of MSN dysfunction in HD are secondary to disturbances of astrocyte Kir4.1. These 
data thus reveal astrocytes as potential cellular targets for therapeutic development in HD.
Results
We performed evaluations for R6/2 and Q175 mouse models of HD7,13,14. To avoid 
repetition, the text mainly reports data from WT and R6/2 mice at presymptomatic (P30) and 
symptomatic ages (P60–80; Supp Fig. 1a-d). However, key experiments were repeated with 
WT, heterozygous and homozygous Q175 mice at ages of 2–3 months, 6–7 months and 9–
12 months. These data are reported throughout the results and the Supplementary 
information.
No striatal astrogliosis in R6/2 mice at symptomatic ages
Reactive astrogliosis is associated with injury, neuroinflammation and disease and is 
classically regarded as being accompanied by easily detectable increases in astrocyte GFAP 
expression and morphological changes15. Using immunohistochemistry we detected only 
low levels of striatal GFAP immunostaining that was indistinguishable in R6/2 and WT 
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mice at P60–80 (Fig. 1a; n = 4 mice), implying little or no astrogliosis. Quantification of 
individual GFAP expressing astrocytes from WT and R6/2 mice at P70 provided no 
evidence of cellular hypertrophy or any detectable morphological changes associated with 
classical astrogliosis15 (Fig. 1b–e; n = 4 mice; 32 astrocytes). Using Ki67 immunostaining 
we also found no evidence of astrocyte proliferation in R6/2 mice at P60–80, or even at 
P110, a time of considerable tissue loss (Supp Fig. 2; n = 5). pSTAT is a transcriptional 
regulator that is strongly increased during classical astrogliosis19, but we found no evidence 
for upregulation of pSTAT3 in R6/2 mice at P60–80 (data not shown; n = 4). Lastly, using 
Western blot analysis of CP tissue, we found no evidence for increased GFAP expression in 
R6/2 mice at P60–80 relative to WT littermates (Fig. 1f; n = 4). In contrast, in older R6/2 
mice (P104–110), when overt striatal atrophy and neurodegeneration has occurred, there was 
clear evidence of astrogliosis in the form of GFAP upregulation (Supp Fig. 3).
Our analysis of astrogliosis is consistent with early observations on GFAP expression in 
R6/2 mice7 and suggests that HD–like symptoms in the mice occur before overt astrogliosis. 
In humans, a doubling of GFAP expression is observed in late stages of HD (Grades 3 and 
4), but at Grade 0 no statistically significant differences from control are reported10.
Striatal astrocytes display altered properties in HD mice
In contrast to GFAP, which marked only a small number of striatal astrocytes (Fig. 1a; n = 
6), Aldh1L116, GS and S100β marked most striatal astrocytes (Supp Fig. 4). Co–localization 
experiments showed that all GS expressing astrocytes were Aldh1L1 positive, and all 
Aldh1L1 expressing astrocytes were also S100β positive (Supp Fig. 5; n = 4). Next, we used 
triple color IHC to determine if GFAP, Aldh1L1, GS and S100β–expressing astrocytes (in 
green) contained mHTT nuclear inclusions (nuclei in blue, inclusions shown in white; Fig. 
2a) using the monoclonal mEM48 antibody that recognizes exon 1 of mHTT17. We found 
that the nuclei of GFAP, S100β, GS and Aldh1L1–labelled astrocytes were positive for 
mHTT (Fig. 2a; n = 4), reminiscent of past work9,10.
Using morphological and electrophysiological criteria18 to identify astrocytes in brain slices 
(Supp Fig. 6), we found that R6/2 astrocytes were significantly more depolarized than WT 
astrocytes at P60–80 (resting membrane potentials were −76 ± 0.7 and −71 ± 0.8 mV for 
WT and R6/2 astrocytes, respectively; n = 79 & 67, P < 0.0001 using a two tailed Mann–
Whitney test). These differences were not observed at P30 (Fig. 2b,c; Supp Table 1; n = 53–
55, P = 0.794 using a two tailed Mann–Whitney test). At these same ages, striatal R6/2 
astrocytes displayed significantly lower membrane conductances (Fig. 2d) and showed 
higher membrane resistances (Fig. 3a–d; Supp Table 1; n = 53–79, P < 0.0001 using a two 
tailed Mann–Whitney test). There were no significant differences in membrane capacitance 
at P30 or P60–80 (capacitance was 18–19 pF in each case, data not shown; n = 53–79 cells).
Differences in striatal astrocytes between WT and R6/2 mice at P60–80 did not extend to 
hippocampal astrocytes from R6/2 and WT mice at P30 and P60–80 (Supp Table 1; n = 7–
11). To ascertain whether the differences between WT and R6/2 striatal astrocytes were 
restricted to the R6/2 mouse model, we repeated all the electrophysiology experiments in 
WT, heterozygous and homozygous Q175 mice at 2–3, 6–7 and 9–12 months of age (Supp 
Tables 2–3; n = 11–34). These data show that astrocytes from Q175 homozygous and 
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heterozygous mice are also significantly more depolarized and display lower membrane 
conductances at ages when HD–like symptoms are manifest, i.e. 6–7 months for 
homozygous mice and 9–12 months for heterozygous mice (Supp Tables 2–3; n = 11–34).
Striatal astrocytes from HD mice display reduced Kir4.1 currents
Weakly inwardly rectifying Kir4.1 channels are the predominant K+ channels in 
astrocytes19-21 and underlie their negative resting membrane potentials near the potassium 
equilibrium potential22 (EK). We explored the possibility that astrocytes from HD mouse 
models may display reduced Kir4.1 currents. To this end, we measured I/V relations before 
and during extracellular applications of the Kir4.1 channel blocker Ba2+ (100 μM), and by 
subtracting the I/V traces (Supp Fig. 7) we isolated Ba2+–sensitive Kir4.1 currents, which 
displayed reversal potentials (Erev) close to EK (Fig. 3e,f; Supp Fig. 7)23. We repeated these 
experiments for WT and R6/2 mice at P30 and P60–80, as well as for WT, heterozygous and 
homozygous Q175 mice at 2–3, 6–7 and 9–12 months of age (Fig. 3e,f; n = 12–24; Supp 
Tables 1–3). We found significant (up to 30%) reductions in Ba2+–sensitive currents in 
astrocytes from HD–model mice (both R6/2 and Q175) at symptomatic ages, but not at ages 
that were pre symptomatic (Fig. 3e,f; n = 12–24; Supp Tables 1–3). We also used 
nortriptyline (NOR; 300 μM) which preferentially blocks Kir4.1 channels over other inward 
rectifiers24,25. The use of NOR showed that Kir4.1 currents were significantly reduced in 
R6/2 mice relative to WT at P60–80 (Supp Table 4; n = 13,14).
We detected significant astrocyte electrophysiological changes in the 9–12 month age group 
for heterozygous Q175 mice. How does this relate to symptoms in these mice? Past work 
shows that heterozygous Q175 mice display significant behavioral changes at less than 6 
months of age14. However, in other tests they display no phenotypic changes even when 
they are 12 months old, and they don't show decreased body weight until they are ∼ 1 year 
old14 (but see ref 13). Moreover, at a cellular level MSN properties are altered at different 
ages. Thus, these mice display a phenotypic spectrum that occurs at different ages14. We 
also make no claim that the astrocyte dysfunction we report is the only driver of behavioral/
systemic disorder in HD mouse models.
Mechanistic insights on reduced Kir4.1 currents in R6/2 mice
We used quantitative PCR (qPCR) to determine if Kir4.1 mRNA levels were decreased in 
R6/2 striatal tissue relative to WT (the gene name for Kir4.1 is KCNJ10). Although there 
was a trend for Kir4.1 mRNA levels to be ∼10% lower, this did not reach statistical 
significance (Fig. 4a; n = 7, 5; P = 0.1688 unpaired Student's t test). Consistent with our 
Western blot data (Fig. 1g), we found that GFAP mRNA levels were also not significantly 
changed in R6/2 mice relative to WT (Fig. 4b; n = 7, 5; P = 0.0845 unpaired Student's t test), 
and consistent with past studies26 we found that Glt1–1 mRNA levels were significantly 
reduced in R6/2 mice (Fig. 4c; P = 0.0267 unpaired Student's t test). For the aforementioned 
experiments, Kir4.1 mRNA levels were analyzed in relation to GAPDH, ATP5B and UBC 
as controls (Supp Fig 8a), because these mRNAs are among the most stable in mouse 
models of HD27. Thus Kir4.1 mRNA levels are not significantly reduced in R6/2 mice at 
symptomatic ages (P60–80), a finding that was reproduced with the WT, heterozygous and 
homozygous Q175 mice aged 10 months (Supp Fig. 8b; n = 4–5). This recalls transcriptome 
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analysis of R6/2 mice at ∼P63, but differs from human postmortem analysis, where Kir4.1 
mRNAs were significantly, albeit subtly, reduced in Grade 3 stages of HD28.
mHTT can affect the function of some intracellular ion channels29, prompting us to explore 
whether mHTT directly affects the function of Kir4.1 channels. In order to test for this, we 
determined if mHTT with 145 polyglutamines (mHTT–Q145) affected Kir4.1–GFP channel 
function in HEK–293 cells. We measured equally sized total and Ba2+–sensitive Kir4.1 
currents in HEK–293 cells expressing Kir4.1–GFP alone or Kir4.1–GFP and mHTT–Q145 
(Fig. 4d–e; n = 15–17). Controls showed that mHTT–Q145 proteins were expressed in 
HEK–293 cells, implying that mHTT–Q145 does not directly affect Kir4.1 ion channel 
function.
We used Western blot analysis to determine if Kir4.1 protein levels were reduced in striatal 
tissue (relative to β–actin); we used Glt–1 as a positive control11 (Fig. 4c). Western blot 
analysis showed significantly reduced levels of Kir4.1 proteins in striatal tissue from R6/2 
mice at P60–80, but not at P30 (Fig. 4g; n = 4). Additionally, Glt–1 protein levels were 
reduced as expected (Fig. 4h; n = 4). Similar data were gathered for Q175 mice (Supp Fig. 
9). We also found that glutamine synthetase (GS) levels were significantly reduced in R6/2 
mice at P60–80 (Fig. 4g; n = 4), but only modestly in relation to the reductions that 
accompany astrogliosis15. Together, the electrophysiology and Western blot data provide 
compelling evidence (Figs. 3–4) for astrocyte Kir4.1 channel dysfunction in HD mouse 
models.
mHTT expressing astrocytes display reduced Kir4.1 immunostaining
Using four color IHC (Fig. 5a,b), we studied astrocyte Kir4.1 expression in single cells 
immunostaining (red) in relation to nuclei (blue), mHTT nuclear inclusions (white) and 
S100β (green) for WT and R6/2 mice at P60–80 (Figs. 3 & 4). In these experiments, mHTT 
nuclear inclusions indicate which cells exhibit nuclear mHTT aggregates, but they do not 
tell us about the larger population of cells that may express soluble mHTT30. In WT mice, 
we observed no nuclear mHTT inclusions and robust expression of Kir4.1 in all S100β 
positive astrocytes (arrows 1–3 in Fig. 5a,c; n = 6 mice). In contrast, in R6/2 mice we 
observed strong nuclear mHTT staining in ∼10% of S100β positive astrocytes at P30, with a 
significant increase to ∼20% at P60–80 (Fig. 5b,c). We quantified Kir4.1 immunostaining in 
S100β positive astrocytes and found that astrocytes that were S100β positive and also 
contained mHTT displayed significantly lower levels of Kir4.1 immunostaining as 
compared with astrocytes in WT mice or astrocytes that did not contain mHTT inclusions in 
R6/2 mice (Fig. 5d). Together, these data show that a significant fraction of R6/2 S100β 
positive astrocytes (∼20%) contain mHTT nuclear inclusions at the age of P60–80, and that 
these astrocytes display significantly reduced Kir4.1 immunostaining (Fig. 5d).
Why is it that ∼20% of S100β positive astrocytes contain mHTT nuclear inclusions (Fig 5c), 
whereas we detected significantly decreased astrocyte Kir.4.1 currents across a sampling of 
all recorded astrocytes? First, astrocytes are coupled by gap junctions31, thus single–cell 
recordings sample a population of astrocytes. Second, mHTT can exist in a soluble form and 
also within inclusions. Third, despite intense study it remains unclear if the major 
pathological form is the cytosolic or the nuclear inclusion version of mHTT30. In order to try 
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and explore the cytosolic form of mHTT we also tested the MW8 antibody, but found that 
this preferentially labeled inclusions (Supp Fig 10). We suggest that many astrocytes may 
contain soluble forms of mHTT not detected by mEM48 and that these lead to Kir4.1 
dysfunction in populations of astrocytes; a subpopulation of these (∼20%) contain mHTT 
nuclear inclusions detectable with mEM48.
Astrocyte deficits are rescued by viral delivery of Kir4.1–GFP
The data reported in the preceding sections strongly suggest that Kir4.1 channel function 
and expression are compromised in striatal astrocytes from symptomatic HD mouse models. 
In light of this, we determined if viral delivery of Kir4.1 would rescue the deficits observed 
in HD mouse models. Detailed work32 with AAV2/5 and the gfaABC1D promoter to drive 
astrocyte specific gene expression suggested that two weeks post infection would be an ideal 
time to use in the present work (in future studies shorter and longer time points will also be 
evaluated). Thus following described methods32, we used adeno associated viruses of the 
2/5 serotype (AAV2/5) that preferentially target astrocytes33,34 together with the gfaABC1D 
promoter to deliver GFP–tagged Kir4.1 channels (Kir4.1–GFP) or cytosolic tdTomato as a 
control (Fig. 6a,b). After injection at P56, AAV2/5 mediated viral transduction lead to 
Kir4.1 and tdTomato expression in S100β positive astrocytes throughout the striatum (Supp 
Fig. 11; n = 4): we estimate that Kir4.1–GFP expressing astrocytes were present in 83 ± 1% 
(n = 4) of the striatal volume. Kir4.1–GFP was not detected within striatal neurons (data not 
shown). Moreover, in astrocytes that were mHTT positive in R6/2 mice (white arrows 2 & 3 
in Fig. 6b), AAV2/5 Kir4.1–GFP viruses increased Kir4.1 immunostaining to mean levels of 
15.2 ± 0.9 a.u. of fluorescence intensity (n = 35 cells from 4 mice), which was slightly, but 
not significantly, greater than the mean 13.4 ± 0.4 a.u. (n = 147 cells from 6 mice) seen in 
WT mice (Fig. 5d) and was significantly greater than the mean 11.1 ± 0.7 a.u. (n = 52 cells 
from 6 mice) detected in mHTT positive astrocytes from untreated R6/2 mice (Fig. 5d) (P = 
0.0011 with a two–tailed Mann–Whitney test). Thus, AAV2/5 Kir4.1–GFP viruses restored 
Kir4.1 immunostaining in astrocytes with mHTT nuclear aggregates to essentially normal 
levels.
The I/V relations of P60–80 R6/2 striatal astrocytes expressing Kir4.1–GFP were restored to 
levels equivalent to WT mice at P60–80 (Fig. 6c ν Fig. 3c), whereas the I/V relations of 
astrocytes expressing tdTomato were the same as non-injected R6/2 mice at P60–80 (Fig. 
6c). Moreover, expression of Kir4.1–GFP rescued deficits in astrocyte resting membrane 
potentials and macroscopic slope conductance of R6/2 mice (Fig. 6d,e ν Fig. 3d). Finally, 
Ba2+–sensitive currents recorded from R6/2 astrocytes at P60–80 in Kir4.1–GFP expressing 
astrocytes were the same size as those recorded from WT mice, whereas in cells expressing 
tdTomato they were smaller and equal to those measured in un injected R6/2 mice (Fig. 
6f,g,h ν Fig. 4b).
We also carried out controls with the AAV Kir4.1–GFP and tdTomato viruses. Thus, 
AAV2/5 Kir4.1–GFP did not significantly increase total or Ba2+ sensitive currents in WT 
astrocytes (Supp Fig 12a,b). Relative to mice that received AAV2/5 tdTomato, those that 
received Kir.4.1–GFP displayed significant levels of GFP–tagged Kir4.1 and elevated levels 
of total Kir4.1 levels by Western blot analysis (Supp Fig 12c,d). Interestingly, astrocytes 
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expressing Kir4.1–GFP also displayed significantly elevated levels of Glt–1 levels as 
compared to those expressing tdTomato (Supp Fig 12e), implying that restoration of Kir4.1 
function also rescues additional deficits in R6/2 mice. We evaluated whether AAV2/5 
mediated delivery of Kir4.1–GFP caused inflammation in relation to WT and R6/2 mice, as 
well as in relation to R6/2 mice receiving AAV2/5 tdTomato, and found that it did not (Supp 
Fig 13).
Elevated striatal K+ levels in R6/2 mice and effects on MSNs
One of the proposed functions of astrocyte Kir4.1 channels is to maintain extracellular K+ 
levels23. In light of this, we asked whether extracellular K+ levels were elevated in the 
striatum of R6/2 mice at P60–80 relative to WT mice (Fig. 7a). Using K+ selective 
microelectrodes22,35 inserted into the striatum in vivo, we found that K+ concentration was 
significantly elevated from 1.5 ± 0.2 mM (n = 6) in WT mice to 2.9 ± 0.3 mM (n = 5) in 
R6/2 mice at P60–80 (Fig. 7b; P = 0.0041 unpaired Student's t test). This increase in R6/2 
mice was ameliorated by injecting AAV2/5 Kir4.1–GFP (K+ concentration was 1.8 ± 0.3 
mM; n = 5, P > 0.05 compared to WT, unpaired Student's t test). The doubling of the 
extracellular K+ concentration would lead to a significant depolarization of EK, hence, this 
discovery in R6/2 mice would be expected to alter neuronal excitability36.
Interestingly, one of the features of HD mouse models is that MSNs are 3 to 13 mV more 
depolarized than MSNs in WT mice14,37. We determined if a change in striatal K+ 
concentration from 1.5 to 3.0 mM, as measured in R6/2 mice in vivo (Fig. 7b), could be 
sufficient to reproduce this effect in WT mice. If so, this would suggest that a hitherto 
overlooked underlying initial cause of depolarized MSNs may simply be a change in 
extracellular K+ concentration (Fig. 7b). We made current–clamp recordings from MSNs in 
brain slices from WT mice and measured their resting membrane potentials in a bath 
solution containing 1.5 mM K+, then we switched to 3 mM K+ and recorded a significant 
depolarization of ∼6 mV (Fig. 7e,f; n = 17, P < 0.0001 paired Student's t test). Changing the 
K+ concentration also significantly changed the rheobase (Fig. 7c,d,g; n = 5, P = 0.0032, 
paired Student's t test) – a change that mimics published differences observed for MSNs 
between HD mouse models and WT mice14,37. In summary, subtly elevating the 
extracellular K+ concentration to the same levels that we measured in R6/2 mice in vivo 
(Fig. 7a,b) can phenocopy in WT mice several key MSN properties reported in HD mouse 
models.
Attenuation of phenotypes in R6/2 mice by delivery of Kir4.1–GFP
A salient feature across mouse models of HD is that MSNs display depolarized membrane 
potentials by up to 12 mV8. We considered the possibility that reducing astrocyte Kir4.1 
function with Ba2+ in WT slices may reveal secondary consequences for MSNs, but this 
experiment is unfeasible (Supp Fig. 14). We therefore used a different approach to explore 
how dysfunction of astrocyte Kir4.1 channels in R6/2 mice affected MSNs. We measured 
deficits in MSN properties in HD mice in relation to WT, and then sought to determine if 
they can be rescued with AAV2/5 Kir4.1–GFP (Fig. 6). Recalling past work8, we found that 
MSNs from R6/2 mice were significantly depolarized by ∼12 mV, were more excitable and 
displayed higher membrane resistances compared to WT (Fig. 7h–j; n = 13–17). Next, we 
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injected R6/2 mice with AAV2/5 Kir4.1–GFP or AAV2/5 tdTomato and then recorded from 
MSNs two weeks later (Fig. 7k–m; n = 19–20). We found that MSN properties were 
significantly improved in mice that had been injected with AAV2/5 Kir4.1–GFP as 
compared to AAV2/5 tdTomato (Fig. 7k–m). Indeed, in the case of resting membrane 
potentials, expression of Kir4.1–GFP rescued MSNs to WT levels (Fig. 7h ν Fig. 7k), but 
the rescue was partial in the case of excitability and membrane resistance (Fig. 7l,m). The 
differences in MSN properties observed by delivering Kir4.1–GFP channels to striatal 
astrocytes in R6/2 mice (Fig. 7) suggest that Kir4.1 channels may be promising targets to 
correct aspects of MSN dysfunction in HD, which in the simplest interpretation appear to 
involve astrocytes and neurons. It is likely that restoring astrocyte Kir4.1 function restores 
their homeostatic functions within the striatum, which has beneficial effects on MSNs. 
Additionally, neuron–astrocyte contacts can regulate ion channel expression within 
astrocytes21, raising the possibility that neuronal properties may be changed by contacting 
astrocytes with normal Kir4.1 levels38.
We next determined whether bilateral striatal injections of AAV2/5 Kir4.1–GFP to recover 
astrocyte Kir4.1 currents (Fig. 6) could lead to attenuation of HD phenotypes in male R6/2 
mice. We assayed motor coordination using the rotarod39 without practice sessions. 
Although practice can improve rotarod performance, untreated R6/2 mice sometimes seized 
and died immediately after falling off the rotarod and multiple training sessions would have 
exacerbated this. We used the paw clasp test (Supp Fig. 15) to measure dystonia/
dyskinesia7. We used footprint analysis to evaluate gait. Using these assays, we compared 
WT with R6/2 mice, and also with R6/2 mice that had received either AAV2/5 Kir4.1–GFP 
or AAV2/5 tdTomato injected bilaterally into the striatum at P56. First, in all assays the 
R6/2 mice displayed severe deficits relative to WT mice, emphasizing HD phenotypes by 
P92 (Fig. 8, Supp Fig. 15). Second, we found that delivery of Kir4.1–GFP did not improve 
HD phenotypes in the rotarod or paw clasp assays (Supp Fig. 15). Third, using footprint 
analysis we found that Kir4.1–GFP expression improved both stride length and width in 
R6/2 mice to levels that were significantly better than both untreated R6/2 mice and R6/2 
mice injected with AAV2/5 tdTomato (Fig. 8a–c). Fourth, from a specific set of 
experiments, when analyzed at ∼51 days post injection, most of the R6/2 mice that had 
received AAV2/5 Kir4.1–GFP were alive, but most of the R6/2 mice that had received 
AAV2/5 tdTomato were dead, as expected for R6/2 mice of this age40 (P < 0.0063, two–
sided Fisher's Exact test; Fig. 8d). However, there were no differences in body weight 
between these groups for dead or living mice (Fig. 8e). For another different set of 
experiments, survival analysis also confirmed the increased longevity of R6/2 mice injected 
with AAV2/5 Kir4.1–GFP relative to those with AAV2/5 tdTomato (Fig. 8f; n = 11 & 10), 
such that by 115 days after birth (∼60 days post injection), ∼80% of the R6/2 mice that had 
received AAV2/5 Kir4.1–GFP were alive, whereas, as expected40, only 22% of mice that 
received AAV2/5 tdTomato were alive (P < 0.0001, two–sided Fisher's Exact test). This was 
reflected by an increase in the average lifespan by ∼8 days from 98.7 ± 5.7 to 116.5 ± 4.5 
days for R6/2 mice that received tdTomato or Kir4.1–GFP, respectively (Fig. 8f; P = 0.0306 
with a one-tailed unpaired Mann-Whitney test). Thus, differences observed by delivering 
Kir4.1–GFP channels to striatal astrocytes in R6/2 mice (Fig. 8) suggest that motor 
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phenotypes in HD and HD–models are due to complex, multifactorial mechanisms that are 
likely to involve dysfunction of multiple cell types.
Discussion
There are eight findings from this study. First, striatal astrocytes from R6/2 mice contain 
mHTT nuclear inclusions at P60–80, i.e. when the mice are symptomatic, but before 
detectable evidence of astrogliosis. Second, striatal astrocytes from symptomatic R6/2 mice 
display depolarized membrane potentials and lower membrane conductances. Third, striatal 
astrocyte electrophysiological defects can be accounted for by lower functional expression 
of Kir4.1 channels, and can be recovered by AAV2/5 mediated delivery of Kir4.1 to 
astrocytes. Fourth, extracellular K+ buffering is reduced in the brains of R6/2 mice as 
evidenced by significantly elevated extracellular K+ levels in the striatum at P60–80. Fifth, 
increasing K+ concentrations in brain slices from healthy WT mice reproduced some of the 
features of altered MSN excitability observed in R6/2 mice. Sixth, all the key cellular 
observations with R6/2 model mice are reproduced in the Q175 mice when they are 
symptomatic, implying that these observations are not restricted to the aggressive R6/2 
mouse model of HD. In future studies, many more aspects of astrocyte biochemistry and 
physiology need to be explored in both HD mouse models to determine if some phenotypic 
changes can be detected at presymptomatic stages in the less aggressive Q175 mode. If this 
were to be the case, then this would provide a basis to choose one mouse model over the 
other. Seven, expression of Kir4.1–GFP in astrocytes also rescued some MSN deficits 
observed in R6/2 mice. Eight, expression of Kir4.1–GFP within striatal astrocytes in vivo 
attenuated a HD–like motor deficit and prolonged survival in R6/2 mice. When interpreting 
these findings, it is important to remember that the functional measurements relied on 
whole-cell patch clamp electrophysiology that leads to intracellular dialysis of neurons and 
astrocytes. Therefore, the data need to be considered with this caveat in mind.
The study of HD is a rapidly developing field, but only limited attention has focused on 
astrocytes and their potential roles. Past studies have shown a disruption of astrocyte Glt–1 
function11,41-43 in HD mouse models, but the present study was motivated by the discovery 
that post mortem specimens from HD patients show mHTT inclusions in striatal 
astrocytes9,10. Moreover, expression of mHTT in astrocytes lead to death of co–cultured 
striatal neurons9, and expression of mHTT in astrocytes in vivo by employing the GFAP 
promoter lead to reduced Glt–1 expression10, age–dependent HD–like pathology and 
premature mortality11. By their nature these studies do not prove that astrocyte physiology is 
altered in, or if astrocytes contribute to, conventional mouse models of HD. Our aim was to 
confirm or refute the hypothesis that astrocyte physiology is altered in standard models of 
HD. Our second aim was to evaluate and provide hypotheses for exploring plausible 
causative roles of astrocytes in HD.
We found that GFAP did not label the majority of astrocytes in the mouse striatum. On the 
other hand, Aldh1L1, S100β and GS labeled most striatal astrocytes, recalling past 
experiences with Aldh1L116. In R6/2 mice, mHTT nuclear inclusions were detected at P30 
in ∼10% of S100β positive astrocytes prior to the onset of symptoms and prior to detectable 
neurodegeneration. The astrocyte nuclear load of mHTT inclusions increased with time with 
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the onset and progression of symptoms and pathology in both R6/2 and Q175 mice. At a 
time point concomitant with the onset of symptoms (P60–80), significantly more astrocytes 
(∼20%) displayed mHTT inclusions and exhibited significant reductions in important 
functional proteins such as GS, GLT–1, S100β and Kir4.1 than at a pre–symptomatic stage 
(P30). Single–cell analyses demonstrated a positive relation between the presence of mHTT 
nuclear inclusions in astrocytes and reductions in levels of Kir4.1 immunostaining. In 
contrast, GFAP levels were not significantly altered at this time (P60–80) and there were no 
other major phenotypic changes associated with astrocyte reactivity15. These findings 
suggest that mHTT is associated with early intrinsic disruption of the expression of 
important astrocyte functional proteins (e.g. Kir4.1, Glt–1), which alters astrocyte function 
without triggering astrogliosis. If so, later signs of astrogliosis in R6/2 mice at greater than 
P100 could derive from external cues resulting from increasingly severe local 
neurodegeneration. These data imply that pursuing therapeutic strategies aimed at early 
stages of the disease may be useful to correct functional deficits within astrocytes, with the 
possibility that subsequent astrogliosis may be reduced. Such approaches may be more 
fruitful than targeting the mechanisms of astrogliosis, which appears to be a 
heterogeneous44,45, context dependent and often protective response to a wide range of 
disparate insults15.
It is well established that in HD mouse models8 MSNs are depolarized by up to ∼12 mV, 
display lower membrane conductances and display lower K+ currents46,47. In accord with 
the MSN data, using two HD mouse models before and during HD–like symptoms, we 
found that striatal astrocytes are depolarized by +5 mV and display lower membrane 
conductances by up to 20%. Our experiments show that the underlying cause of both these 
defects can be attributed to a loss of Kir4.1 functional expression within mHTT expressing 
striatal astrocytes. This result has clear implications for understanding HD and other 
neurological and psychiatric disorders, and speaks to the realization that astrocytes act in 
partnership with neurons in health and disease2,3. In future work, further mechanistic studies 
are needed to explore how Kir4.1 function and expression are robustly reduced in HD mouse 
models, even though mRNA levels did not decrease significantly in our evaluations. One 
possibility is that mHTT affects the trafficking or processing of Kir4.1 channels.
The loss of Kir4.1 currents in striatal astrocytes predicts reduced spatial K+ buffering and 
higher ambient K+ levels in HD mouse models23. We tested for this and found that the 
extracellular K+ concentration was doubled in R6/2 mice. This prompted us to explore the 
impact of increased K+ (from 1.5 to 3.0 mM) on the properties of MSNs in WT mice. To our 
surprise, we found that these changes reproduced the excitability features of MSNs 
described in a variety of HD mouse models8. Interestingly, brain wide astrocyte specific 
deletion of Kir4.1 channels causes mice to fall over, display hind leg splaying and 
“wobble”48, features that broadly phenocopy HD motor phenotypes in R6/2 mice7. To 
further explore the relationship between astrocyte Kir4.1 channels and HD–like phenotypes 
in R6/2 mice, we delivered Kir4.1–GFP channels to striatal astrocytes and found that one 
motor symptom (stride length and width) was attenuated by this approach. It seems unlikely 
that all motor phenotypes can be recovered by any one striatal–specific intervention, because 
R6/2 mice have multiple abnormalities. Moreover, we found that MSN membrane properties 
were also partly recovered by astrocytic expression of Kir4.1–GFP. These tantalizing 
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findings strongly support the notion that HD–like phenotypes derive from neuronal 
dysfunction that also involves astrocyte disturbances, pointing towards Kir4.1 as a 
promising target to potentially correct some deficits in HD.
To date, research efforts have been focused largely on identifying neuronal mechanisms to 
account for changes in MSN properties in HD models. Our findings provide compelling 
evidence for the novel hypothesis that key aspects of altered MSN excitability in HD are 
secondary to disturbance of astrocyte maintenance of extracellular K+, which may have 
secondary consequences for MSNs such as through glutamate transport. These findings have 
important implications for therapeutic strategies in HD and suggest that therapeutics that 
target only disturbances of MSNs are likely to be inadequate or suboptimal as regards 
restoring function and ameliorating disease symptoms.
Online Methods
Mouse models
R6/2 and non–transgenic control mice were obtained from in house breeding (JAX, Bar 
Harbor, Maine). In some cases, R6/2 and WT mice were purchased from Jackson 
Laboratories directly at the appropriate ages. Mice were genotyped by PCR and CAG repeat 
length determined by Laragen (Culver City, CA). The CAG repeat length of mutant 
offspring was between 118 and 140. Q175 mice, homozygous, heterozygous and non–
transgenic controls were also bred in house by crossing heterozygous males and females as 
obtained from JAX. Mice were genotyped by PCR and CAG repeat length determined by 
Laragen. The CAG repeat length of mutant offspring was between 170 and 208. 
Experiments conducted according to protocols approved by the Chancellor's Animal 
Research Committee of the Office for Protection of Research Subjects at UCLA.
Histology and immunohistochemistry
For histological evaluations, mice were euthanized by barbiturate overdose and perfused 
transcardially with PBS, followed by 10% buffered formalin (Fisher). Brains were removed, 
post–fixed overnight and cryoprotected in buffered 30% sucrose for at least 2 days. 40 μm 
coronal frozen sections were prepared using a cryostat microtome (Leica, Nussloch 
Germany) and either stained with cresyl violet or processed for brightfield or fluorescence 
immunohistochemistry. Briefly, brightfield immunohistochemistry was performed using 
biotinylated secondary antibodies (Vector, Burlingame, CA), biotin–avidin–peroxidase 
complex (Vector) and diaminobenzidine (DAB, Sigma) as the developing agent. 
Fluorescence immunohistochemistry was performed using secondary antibodies tagged with 
Alexa 488 (green), Alexa 350 (blue) (Molecular Probes, Grand Island NY), Cy3 (red), or 
Cy5 (far–red) (Vector Labs, Burlingame CA). The nuclear stain, 4′,6′–diamidino–2–
phenylindole dihydrochloride (DAPI; 2 ng/ml; Molecular Probes), was used to label nuclei. 
The following primary antibodies were used: rabbit anti–GFAP (1:1000, Dako, Carpenteria 
CA); mouse anti–GFAP (1:500, Sigma, CA); rabbit anti–Kir4.1 (1:400, Alomone Labs, 
Jerusalem, Israel); sheep anti–S100β (1:600, QED Bioscience; Atlanta, GA); mouse anti–
S100β (1:400, Sigma); rabbit anti–GLT–1 (1:1000, Millipore); mouse anti–glutamine 
synthetase (1:400, Millipore; Billerica, MA); rabbit anti–glutamine synthetase (1:400, 
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Millipore); mouse anti–mHTT (clone EM48; 1:200, Millipore); mouse anti–mHTT (clone 
MW8; 1:50, DSHB, Iowa), rabbit anti–Iba1 (1:1,000, Wako), rat anti–CD68 (1:150, 
Serotec), rabbit anti–Aldh1L1 (1:200, Abcam, Cambridge MA); mouse anti–Ki67 (1:1000, 
Vector Labs; (Burlingame, CA); rabbit anti–pSTAT3 (1:1000, Millipore). Stained sections 
were examined and photographed using brightfield, fluorescence and laser scanning 
confocal microscopy (Zeiss, Oberkochen Germany).
Quantitative morphometric evaluations
The number of astrocytes with mHTT nuclear inclusions was quantified by evaluating stacks 
of consecutive 1 μm confocal microscopic images acquired with a 63X objective lens and 
taken from random fields of caudate putamen that had been triple stained for mHTT, S100β 
and DAPI. All S100β stained astrocytes within a 63X field were evaluated. Astrocytes with 
one or more mHTT positive inclusion bodies were scored as mHTT positive. At least 30 
astrocytes were evaluated per animal and at least 4 animals were evaluated per group. The 
relative intensity of Kir4.1 immunofluorescence was quantified in astrocytes that were 
positive or negative for mHTT by evaluating 1 μm confocal microscopic images acquired 
with a 63X objective lens and taken from random fields of caudate putamen that had been 
quadruple stained for Kir4.1, mHTT, S100β and DAPI. S100β positive astrocytes were 
identified and classified as mHTT positive or negative. The area of individual astrocyte was 
then traced on the basis of S100β staining followed by measuring the integrated density of 
the Kir4.1 immunofluorescence using Image J software v1.30 (NIH).
Western blot analysis
For evaluation of protein expression by Western blot analysis, mice were euthanized by 
barbiturate overdose and brains rapidly removed and placed into ice cold PBS. Caudate 
putamen fresh tissue was rapidly dissected bilaterally in PBS on ice under 10X 
magnification (Zeiss, Oberkochen Germany) and tissue samples were rapidly frozen on dry 
ice. Total protein was extracted from individual tissue samples using a lysis buffer (50 mM 
Tris–HCL, 150 mM NaCl, 1% Nonidet P–40, 10 mM NaF, 10 mM EDTA, 0.5 mM 
dithiothreitol (DTT), 1 mM sodium orthovanadate Na3VO4, 1 mM phenylmethlsulfonyl 
fluoride (PMSF), 4 μg/ml leupeptin and 4 μg/ml pepstatin A, pH 7.4) and centrifuged at 
12,000 g for 25 minutes at 4°C. The supernatant was used for measurements of protein. 
Protein concentration was determined using a Bio–Rad DC protein kit (Bio–Rad 
Laboratories, Hercules, CA). Protein preparations were separated by sodium dodecyl sulfate 
polyacrylammide gel electrophoesis (SDS–PAGE) and transferred to a polyvinlyidene 
difluoaride (PVDF) membrane and blocked with 5% nonfat milk TBST buffer and probed 
using various antibodies. The primary antibodies used for Western blotting were: rabbit 
anti–GFAP (1:1000, Dako); rabbit anti–Kir4.1 (1:1000, Alomone Labs); mouse anti–S100 β 
(1:800, Sigma); rabbit anti–Glt1 (1:10,000, Millipore); mouse anti–glutamine synthetase 
(1:1000, Millipore); rabbit anti–actin (1:500; Sigma). Western blots were visualized using 
Amersham ECL Western Blotting Analysis System (Amersham Pharmacia Biotech) and 
exposed to Kodak X–ray film. Equivalence of protein loading was corrected for by probing 
for β–actin. For quantification, the optical density of the gel bands was determined using 
ImageJ Software v1.30 (NIH).
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Preparation of brain slices for electrophysiology
Striatal slices were prepared from P30 to P80 wild type and R6/2 mice. Briefly, animals 
were deeply anesthetized and decapitated. The brains were placed in ice–cold modified 
artificial cerebrospinal fluid (aCSF) containing (in mM); 194 sucrose, 30 NaCl, 4.5 KCl, 1 
MgCl2, 26 NaHCO3, 1.2 NaH2PO4 and 10 D–glucose, and cut into 300 μm thick coronal 
slices containing the striatum and cortex. For Q175 mice which were older than 6 months, 
the cutting buffer used protective artificial cerebrospinal fluid (aCSF) of the following 
composition (in mM): 92 N–methyl–D–glucamine (NMDG), 2.5 KCl, 1.25 NaH2PO4, 30 
NaHCO3, 20 HEPES, 25 glucose, 2 thiourea, 5 Na–ascorbate, 3 Na pyruvate, 0.5 CaCl2, and 
10 MgSO4.7H2O. The pH of the solution was titrated to 7.3–7.4 with concentrated HCl 
(which provides Cl− counter–ions for NMDG). Brain slices were allowed to equilibrate for 
at least 1 h at room temperature in normal aCSF containing (in mM); 124 NaCl, 4.5 KCl, 2 
CaCl2, 1 MgCl2, 26 NaHCO3, 1.2 NaH2PO4 and 10 D–glucose continuously bubbled with a 
mixture of 95% O2/5% CO2 gas.
Electrophysiological recording from astrocytes and MSNs in brain slices
For striatal astrocyte recordings from R6/2 and Q175 mice, currents were measured in 
whole–cell mode using pipettes with a typical resistance of 5–6 MΩ when filled with 
internal solution containing (in mM): 130 KCl, 2 MgCl2, 10 HEPES, 5 EGTA, 2 Na–ATP, 
0.5 CaCl2, with pH set to 7.3. Cells were visualized with infrared optics on an upright 
microscope (BX51WI, Olympus). pCLAMP10 software and a MultiClamp 700B amplifier 
was used for electrophysiology (Axon Instruments). For striatal medium spiny neuron 
recordings, the ACSF contained the following (in mM): 125 NaCl, 2.5 KCl, 2 CaCl2, 1 
MgCl2, 25 NaHCO3, 1.25 NaH2PO4, and 12.5 glucose. Pipettes were filled with a K+ 
internal solution consisting of (in mM) 135 K–gluconate, 5 KCl, 0.5 CaCl2, 5 HEPES, 5 
EGTA, 2 Mg–ATP, and 0.3 Na–GTP, pH 7.3 adjusted with KOH.
In vivo K+ concentration measurements
K+–sensitive electrodes were made according to a procedure described earlier22,49,50. In 
short, double–barreled glass capillaries (borosilicate theta glass, OD 1.5 mm, ID 1 mm, 
septum 0.2 mm, Warner Instruments Inc., Hamden CT) were washed for 6–24 hours in 1 M 
HCl and rinsed in 70% ethanol. Next they were dried for 6–8 hours at 100–120°C and stored 
for up to 4 weeks in desiccated containers. Pipettes were pulled (DMZ Universal Puller, 
Zeitz, Martinstried, Germany) from these capillaries and tips were broken under a 
stereomicroscope until each barrel had a 1–2 μm opening. After filling the tips for a length 
of ∼1 cm with silanization solution I (5% dimethyldichlorosilane in heptane, Sigma–
Aldrich), the microelectrodes were dried at 100–120°C for 6–10 hours. The final step of the 
K+–electrode production was done directly before use. The tip of one barrel was filled for a 
length of 2–10 μm with the K+–ionophore I–cocktail B (5% valinomycin, 93% 1,2–
dimethyl–3–nitrobenzene, 2% potassium tetrakis(4–chlorophenyl)borate, Sigma Aldrich), 
and backfilled with 200 mM KCl; the other barrel (reference electrode) was filled with 
saline solution (150 mM NaCl). The potential over the two barrels was measured using 
AgCl–electrodes with a high impedance differential amplifier (model 3000, A–M Systems, 
Carlsborg, WA). Signals were filtered with a 0.1 Hz low–pass filter (on amplifier) and 
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sampled at 1 Hz (NI USB–6009 DAC–board and Labview software, National Instruments, 
Austin TX) and stored for later analysis. Analyses was made using Microsoft Excel 
(Microsoft, Albuquerque NM). The K+–electrodes were calibrated by stepping the 
electrodes through a series of solutions with different K+–concentrations (KCl in mM: 100, 
30, 10, 3, 1, and 0.3; NaCl was added to each solution to bring the ionic strength to a total of 
100 mM; pH 7.3, buffered with 10 mM HEPES). The relationship between concentration 
and voltage over both barrels was derived using the Nicolsky–Eisenman equation. Only 
electrodes with at least a 50 mV/p[K+] and linear response in the range from 1–3 p[K+] were 
used.
Surgeries were performed under aseptic conditions on the various mice (see Results) 
according to a protocol approved by the University of California, Los Angeles Chancellor's 
Animal Research Committee. Each animal was deeply anesthetized with isoflurane and 
affixed in a stereotaxic frame (Stoelting Co., Wood Dale, IL). Body temperature was 
maintained at 36–37°C (measured rectally) using a water circulating heating pad. For 
placement of the K+–electrode we used coordinates as described earlier to record evoked 
field potentials from the striatum. To assure the correct location of the K+–electrode, we 
stimulated the cortico–striatal pathway via a stimulus electrode (bipolar twisted pair 
tungsten, Plastics One, Roanoke, VA) placed in the prelimbic area of the medial prefrontal 
cortex (1.7–2.1 mm anterior to bregma, 0.4 lateral to midline, 2.0 mm ventral to the cortical 
surface, ipsilateral to the striatal recording hemisphere) to evoke field potentials in the 
striatum. While stimulating the cortico–striatal pathway (300 μs pulse width, 400 mA pulse 
amplitude every 30 s, with a 365 stimulus isolator, WPI, Sarasota, FL) the K+ electrode was 
placed in the rostral area of the dorsal striatum at an angle of 20° in the coronal plane (0.6–
1.1 mm anterior to bregma, 1.0–3.0 mm lateral to midline, 1.5–4.0 ventral to the cortical 
surface). Large evoked field potentials recorded with the reference channel of the K+–
electrode confirmed the correct striatal placement of the electrode. After correct placement, 
the stimulation was switched off, we waited 25–30 min for a stable baseline (which typically 
happened in 10 min) and then the local K+ concentration was measured. After the 
measurements, the K+–electrode was removed and calibrated (see above). Results were only 
accepted if all calibration points before and after the in vivo measurements showed a 
deviation of less than 10%.
HEK–293 cell culture, transfection and whole–cell voltage–clamp recordings
HEK–293 cells (ATCC) were maintained in 75 cm2 cell culture flasks in Dulbecco's 
modified Eagle's medium/F12 media with Glutamax (Invitrogen) supplemented with 10% 
Fetal Bovine Serum and 1% penicillin/streptomycin. Cells were prepared for transfection by 
plating onto 6 well plates at the time of splitting, 3 to 4 days before transfection. They were 
transfected at ∼60% confluence. For transient expression in HEK–293, we used ∼0.3 μg of 
plasmid and the Effectene transfection reagent (Qiagen). When appropriate, 100 ng of YFP 
was used as a marker of transfected cells. The manufacturer's instructions (Qiagen) were 
followed. Cells were gently dispersed and plated on poly–D–lysine coated glass coverslips 
(12 mm diameter). HEK–293 cell extracellular recording solution comprised (in mM) NaCl 
147, KCl 2, MgCl2 1, CaCl2 1, Hepes 10, and glucose 10 (pH 7.4), and the pipette solution 
contained (in mM) KCl 154, EGTA 11, and Hepes 10. Whole–cell voltage–clamp 
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recordings were made with 3 to 5 MΩ borosilicate glass electrodes (World Precision 
Instruments), with an Axopatch 200B amplifier controlled by a computer running pCLAMP 
8.1 software via a Digidata 1322A interface (Axon Instruments). Data were filtered at 2 kHz 
and digitized at > 5 kHz. The cells were used 3 days post transfection. Waiting longer than 
this was not possible because the cells became too sick to patch.
AAV 2/5 generation and microinjections in vivo
Adeno–associated viruses of the 2/5 serotype, utilizing the minimal gfaABC1D promoter 
and capable of expressing tdTomato and Kir4.1–GFP specifically within astrocytes were 
generated and employed using described procedures32. R6/2 mice at P56 were used in all 
experiments in accordance with institutional guidelines. All surgical procedures were 
conducted under general anesthesia using continuous isoflurane (induction at 5%, 
maintenance at 1–2.5% vol/vol). Depth of anesthesia was monitored continuously and 
adjusted when necessary. Following induction of anesthesia, the mice were fitted into a 
stereotaxic frame with their heads secured by blunt ear bars and their noses placed into an 
anesthesia and ventilation system (David Kopf Instruments, Tujunga CA). Mice were 
administered 0.05 ml of buprenorphine (Buprenex®, 0.1 mg/ml) subcutaneously prior to 
surgery. The surgical incision site was then cleaned 3 times with 10% povidone iodine and 
70% ethanol. Skin incisions were made, followed by craniotomies of 2–3 mm in diameter 
above the left parietal cortex using a small steel burr (Fine Science Tools) powered by a 
high–speed drill (K.1070, Foredom). Saline (0.9%) was applied onto the skull to reduce 
heating caused by drilling. Unilateral viral injections were carried out by using a stereotaxic 
apparatus (David Kopf Instruments) to guide the placement of beveled glass pipettes 
(1B100–4, World Precision Instruments) into the left striatum (the coordinates were (from 
the Bregma): anterior–posterior +0.8 mm, medial–lateral +2 mm, and dorsal–ventral −2.4 
mm from the pial surface). 2 μl of AAV2/5 gfaABC1D TdTomato or AAV2/5 gfaABC1D 
Kir4.1–GFP (∼ 1013 gc/ml) was injected by using a syringe pump (Pump11 PicoPlus Elite, 
Harvard Apparatus). Glass pipettes were left in place for at least 10 mins. Surgical wounds 
were closed with single external 5–0 nylon sutures. Following surgery, animals were 
allowed to recover overnight in cages placed partially on a low–voltage heating pad. 
Buprenorphine was administered 2 times per day for up to 2 days after surgery. In addition, 
Trimethoprim Sulfamethoxazole (40 and 200 mg, respectively per 500 ml water) was 
dispensed in the drinking water for one week. Mice were sacrificed 12–20 days post–surgery 
for electrophysiology or immunohistochemistry (typically 13–15 days). When assessing 
mouse behavior, AAVs were injected bilaterally, but otherwise the protocol was exactly the 
same.
Real–time quantitative PCR (qPCR)
RNA was extracted from striatal tissue samples using Qiagen All Prep DNA/RNA Mini Kit. 
200 ng of mRNA was converted into cDNA using Invitrogen Superscript VILO cDNA 
synthesis kit. cDNA was diluted 1:2 with DEPC treated water. Applied Biosystems Taqman 
probes were used with Taqman Universal Mastermix II, no UNG. qPCR was performed on 
Applied Biosystems 7900HT. Cycling parameters were: 50°C for 2 min, 95°C for 10 min, 
40 repeats of 95°C for 15 seconds and 60°C for 1 minute. GADPH, ATP5B and UBC were 
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used as controls. ΔΔCt method was utilized to determine Relative Fold Expression of 
mRNA.
Behavioral analysis
Limb clasping analysis—Mice were tested for limb clasping behavior by holding the 
mice from the tail and suspending them for 60 seconds. The time taken to clasp their 
forelimbs towards their belly was measured.
Motor function analysis—Mouse motor coordination was assessed by using the 
accelerating rotarod test and footprint test39. Briefly, in the accelerating rotarod test, each 
mouse was placed on a single lane rotarod (Med Associates) for three trials per session. The 
rotarod was set for constant acceleration from 3.0 to 30 rpm over a 5–min period and 
animals were scored in seconds to fall. Mice were not exposed to rotarod practice sessions. 
It is possible that practice may have improved performance in R6/2 mice with AAV–Kir4.1, 
but repeated sessions would likely also have killed a number of the sicker untreated mice. 
We found that some untreated R6/2 mice seized and died immediately after falling of the 
rotarod. Training sessions would have exacerbated this. For gait analysis, each mouse with 
nontoxic red paint on forepaws and black paint on the hind paws was required to run along a 
paper–lined runway (3 feet long and 3 inches wide) to obtain an edible treat in a dark goal 
box at the end. The footprints were analyzed to collect stride length and width and all 
statistical evaluations were performed with unpaired Student's t test. The CAG repeat length 
for the cohort of mice used at the time behavioral analyses were performed was 125.9 ± 0.3 
CAGs (mean ± s.e.m; n = 82 mice) with a range of 119–132 CAG repeats. The behavioral 
experiments were done blind during the day between the hours of 9 am and 9 pm.
Data analysis
All statistical tests were run in GraphPad InStat 3. The graphs were created in Origin 8 and 
assembled in CorelDraw 12. Data are presented as mean ± s.e.m. For each set of data to be 
compared we determined within GraphPad Instat whether the data were normally distributed 
or not. If they were normally distributed we used parametric tests, as listed in the text. If the 
data were not normally distributed we used non parametric tests, as indicated in the text. 
Paired and unpaired Student's two tailed t tests (as appropriate and as indicated in the text) 
and two tailed Mann–Whitney tests were used for most statistical analyses with significance 
declared at P < 0.05, but stated in each case in the figures and text. We decided which test to 
use based on whether the data were normally distributed or not. No statistical methods were 
used to pre–determine sample sizes but our sample sizes are similar to those reported in 
previous publications7,13. Data collection and analysis were not performed blind to the 
conditions of the experiments. However, behavioral analyses and experiments were 
performed blind to the experiment. Data were collected and processed randomly and were 
not assigned to blocks.
Drugs and chemicals
All chemical were purchased from Sigma–Aldrich, Tocris–Cookson or VWR.
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Figure 1. No evidence for astrogliosis at symptomatic ages in R6/2 mice
a. Brain sections from WT and R6/2 mice at P70 stained for GFAP using the DAB reaction. 
b. Representative high magnification views of astrocytes from WT and R6/2 mice at P70. 
R6/2 astrocytes exhibit no evidence of hypertrophy. c. Examples of Sholl analysis for 
astrocytes stained for GFAP from images such as those in b. d. Quantification of GFAP 
area, cells per mm2 and soma size for images such as those in b. e. Quantification of key 
parameters from Sholl analysis for images such as those in c. f. Western blot analysis of 
GFAP expression in WT and R6/2 mice. The gels show data for P60 (in duplicate), whereas 
the bar graph summarizes data at P30 and P60–80 (quantification was achieved by 
normalizing to β–actin). The data shown in this figure were normally distributed and thus 
statistical significance was assessed by unpaired Student's t test; P values are shown. For the 
box and whisker plots shown here and elsewhere, the box is S.E.M and the whisker is S.D.
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Figure 2. Striatal astrocytes from R6/2 mice display nuclear mHTT inclusions, depolarized 
membrane potentials and lower membrane conductances
a. Representative immunofluorescence images showing that GFAP, S100β, GS and 
Aldh1L1 labeled astrocytes (green) from R6/2 mice at P60 contain nuclear mHTT inclusions 
(nuclei were labeled blue with DAPI and mHTT is shown in white). b Representative traces 
of whole–cell voltage–clamp recordings from striatal astrocytes from WT and R6/2 mice at 
P60. The current waveforms show the response to a step depolarization, revealing clear 
differences between WT and R6/2 astrocytes. c. Graphs show striatal astrocyte resting 
membrane potentials for WT and R6/2 mice at the indicated ages. d. Membrane conductance 
between −60 and −50 mV for WT and R6/2 mice at the indicated ages. In c and d, the data 
are presented as mean ± S.E.M. The data in c and d were not normally distributed and 
statistical significance was assessed using the non parametric Two–tailed Mann–Whitney 
test; P values are indicated. For the box and whisker plots shown here and elsewhere, the 
box is the S.E.M and the whisker is the S.D.
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Figure 3. Striatal astrocytes from R6/2 mice display reduced Ba2+–sensitive Kir4.1 currents at 
symptomatic ages (P60–80)
a. I/V plots for WT and R6/2 striatal astrocytes at P30, with representative traces shown to 
the right. b. Histograms for membrane slope conductance calculated from the I/V plots for 
WT and R6/2 mice at P30 (between −120 and +40 mV). c. The graph shows I/V plots for 
WT and R6/2 striatal astrocytes at P60, with representative traces shown to the right. d. 
Histograms for membrane slope conductance calculated from I/V plots for WT and R6/2 
mice at P60 (between −120 and +40 mV). e. I/V plots for Ba2+–sensitive currents for WT 
and R6/2 striatal astrocytes at P30. f. I/V plots for Ba2+–sensitive currents for WT and R6/2 
striatal astrocytes at P60, with representative traces to the right. For the I/V plots, in some 
cases the error bars are smaller than the symbols used. In the case of b,d and f the data were 
not normally distributed and statistical significance was assessed using the non parametric 
Two–tailed Mann–Whitney test; P values are indicated. For the box and whisker plots 
shown here and elsewhere, the box is the S.E.M and the whisker is the S.D.
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Figure 4. Mechanistic studies of Kir4.1 currents in R6/2 mice and HEK–293 cells
a–c. qPCR data for Kir4.1 (a; gene name KCNJ10), GFAP (b) and Glt–1 (c) normalized to 
GAPDH levels for WT and R6/2 striatal tissue at P60–80. Additional RT–PCR experiments 
are shown in Supp Fig 8. d. Representative traces from HEK–293 cells that were 
untransfected, transfected with Kir4.1–GFP alone or cotransfected with Kir4.1–GFP plus 
mHTT(Q145). The current waveforms were elicited by step depolarizations from −160 to 
+60 mV (in 20 mV steps). e. Average I/V plots for experiments like those illustrated in d. f. 
Average Ba2+–sensitive currents for HEK–293 cells expressing Kir4.1–GFP alone and 
Kir4.1–GFP plus mHTT(Q145). g. Representative Western blots and average data for Kir4.1 
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in WT and R6/2 mice at P30 and P60–80. h. As in g, but for GLT–1. i. As in g, but for GS. 
In the case of g and h, the data were not normally distributed and statistical significance was 
assessed using the non parametric Mann–Whitney test; P values are indicated. For the box 
and whisker plots shown here and elsewhere, the box is the S.E.M and the whisker is the 
S.D.
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Figure 5. Kir4.1 immunostaining is reduced in individual striatal astrocytes that contain nuclear 
mHTT inclusions
a. Representative quadruple color immunofluorescence images of WT striatum at P60–80, 
labeled in the indicated colors for DAPI, Kir4.1, S100β and mHTT, showing that no cells 
expressed mHTT. White arrows (1–3) point to S100β positive cells that were also Kir4.1 
positive (red). b. As in a, but for R6/2 striatum at P60–80 and showing that many cells were 
mHTT-positive. Some mHTT positive cells were S100β-positive and had much reduced 
Kir4.1 immunostaining (e.g. white arrow 2), whereas other S100β-positive cells lacked 
mHTT and displayed normal Kir4.1 immunostaining (white arrows 1,3). Are the images 
shown truly representative? When considering this, please note that the absolute intensity in 
the red channel (for Kir4.1) corresponding to cells 1, 2 and 3 was 28.2, 12.4 and 24.3 
arbitrary units. Thus, these representative examples are within the distribution of all the data 
shown in panel d. Note also that none of the images shown in this figure (or elsewhere) have 
been adjusted or altered to exaggerate the fluorescence signal of any component channel. c. 
Plots the percentage of S100β positive cells that also contained mHTT nuclear inclusions in 
WT and R6/2 mice at P30 and P60–80. d. Plots Kir4.1 immunostaining intensity for WT 
mice at P60–80, as well as for S100β positive astrocytes that contained or did not contain 
mHTT. In the case of d the data were not normally distributed and statistical significance 
was assessed using the non parametric Two–tailed Mann–Whitney test; P values are 
indicated.
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Figure 6. AAV2/5 mediated Kir4.1–GFP expression rescues deficits observed in striatal 
astrocytes from R6/2 mice at P60–80
a. The cartoon illustrates the viral constructs employed and the general protocol for AAV 
delivery into the striatum of adult R6/2 mice, which were microinjected at P56 and studied 
14 days later. b. Immunostaining for total Kir4.1 (i.e. native Kir.4.1 and that delivered with 
AAVs) following AAV2/5 Kir4.1–GFP microinjections in R6/2 striatum. Kir4.1 levels are 
restored to those of WT (see Fig. 5a) in mHTT positive astrocytes. c–e. The graphs show 
that AAV2/5 mediated delivery of Kir4.1–GFP to astrocytes significantly restored IV 
relations (c), membrane potentials (d) and membrane slope conductances (e) to control 
levels from WT mice. f–h. Representative traces (f), average I/V plots (g) and analysis of 
Ba2+–sensitive currents (h) shows that AAV2/5 mediated delivery of Kir4.1–GFP restored 
Ba2+–sensitive currents to levels almost identical to WT striatal astrocytes at P60–80. In 
panel g, the WT data are re plotted from Fig. 3f for comparison purposes. In the case of d, e 
and h the data were normally distributed and statistical significance was assessed using the 
unpaired Students t test; P values are indicated.
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Figure 7. Elevated striatal extracellular K+ levels in R6/2 mice in vivo and their effects on WT 
MSN excitability in vitro
a. The cartoon illustrates that we measured K+ concentrations in vivo in the striatum of WT 
and R6/2 at P60–80 using K+ selective microelectrodes. b. The graph shows K+ 
concentration measurements from WT, R6/2 and in R6/2 mice that had received Kir4.1–
GFP. c–g. Representative traces (c,d,e) and average data (f) showing that subtly increasing 
the extracellular K+ concentration from 1.5 to 3.0 mM significantly depolarized MSNs, 
leading to a decrease in the depolarizing current needed to evoke action potentials (c,d) and 
significantly lowering the rheobase (g). h–j. Histograms show differences in the basic 
properties of MSNs from WT and R6/2 mice and the basic MSN properties from R6/2 mice 
that were injected with AAV2/5 Kir4.1–GFP versus those that received AAV2/5 tdTomato. 
In the case of f–j, the data were normally distributed and statistical significance was assessed 
using the paired (f,g) and un paired (h–j) Student's t tests; P values are indicated. For the 
box and whisker plots shown here and elsewhere, the box is S.E.M and the whisker is S.D.
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Figure 8. AAV2/5 mediated Kir4.1–GFP expression attenuates a motor phenotype in R6/2 mice 
at P92
a. Representative raw data for footprint tracks of mice walking on paper with their front and 
rear paws painted with red and black paint, respectively. b–c. Average data from 
experiments such as those shown in (a) for footprint length and width. AAV2/5 Kir4.1–GFP 
significantly improved stride length and width in relation to R6/2 mice and in relation to 
mice that received control AAV2/5 tdTomato virus microinjections. In the case of b and c 
the data were normally distributed and statistical significance was assessed using un paired 
Student's t tests; P values are indicated. d. Statistical analysis of mouse survival for the 
indicated conditions: more mice survived from the pool that received AAV2/5 Kir4.1–GFP. 
e. Analysis of body weights (for dead and living mice) for the indicated conditions: there 
were no differences. f. Survival curves for R6/2 mice that received AAV2/5 tdTomato and 
AAV2/5 Kir4.1–GFP.
Tong et al. Page 28
Nat Neurosci. Author manuscript; available in PMC 2014 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
